TaiGen Biotechnology files IND for influenza antiviral TG-1000

TaiGen Biotechnology Co., Ltd., a Taiwan-based company that focuses on the development and commercialization of treatments for infectious diseases, cancers and diabetic complications, has announced that its influenza antiviral drug TG-1000 has been filed for an Investigational New Drug (IND) application with the US FDA.

For the record, TG-1000 is a pan-influenza antiviral, which abstains viral replication and transmission using a cap-snatching mechanism. The drug is developed to target avian flu H7N9, influenza-A, influenza-B, and Tamiflu-resistant viruses.

As per reports, TG-1000 has successfully received its first US patent from the United States Patent and Trademark Office for prosecuted on Jan 14th, 2020. Following that, in July 2020, a Phase 1 trial was initiated by TaiGen in China which successfully completed the first 4 groups in the single ascending dose part.

Recently, a Phase 2 protocol was submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing.

Commenting on the latest development, Kuo-Lung Huang, Chairman and Chief Executive Officer, TaiGen,  said that their firm is thrilled about the US IND filing for the novel TG-1000 which could come up as a single dose treatment for influenza. TG-1000 IND filing exhibits TaiGen's capacity and experience in research & development of NCEs. 

About TaiGen Biotechnology

TaiGen Biotechnology is a one of the leading biotechnology company in Taiwan. Apart from the novel TG-1000 influenza antiviral therapy, TaiGen has three other in-house discovered NCEs, namely TG-3000, a chemokine receptor antagonist for chemosensitization and stem cell transplantation, Taigexyn®, a new non-fluorinated quinolone present in both intravenous and oral formulations, and Furaprevir, a HCV protease inhibitor for chronic hepatitis infection treatment.

Reportedly, TG-3000 has completed Phase 2 clinical trials, Taigexyn® is being commercialized in the market in Taiwan and the mainland China, and Furaprevir is in its Phase 3 clinical development.

Source Credit: https://www.prnewswire.com/news-releases/taigen-filed-us-ind-for-its-influenza-antiviral-tg-1000-301145272.html